ERBB2 and aneurysmal bone cyst: The treatment landscape for HR+/HER2-aBC has been revolutionized by the introduction of cyclin-dependent kinases (CDK) 4/6 inhibitors (CDK4/6i) in combination with standard endocrine therapy (ET).